HOME >> BIOLOGY >> NEWS
Hypothermia helps brain heal after cardiac arrest, finds University of Pittsburgh study

BOSTON, May 30 Cooling body temperature to levels consistent with hypothermia improves survival when induced after cardiac arrest and also promotes growth factors important for the brains recovery, suggests a study performed by researchers in the department of emergency medicine at the University of Pittsburgh School of Medicine. Preliminary results of their study were reported today at the 2003 Annual Meeting of the Society of Academic Emergency Medicine (SAEM) in Boston.

Although the study involved animals, the findings already had an influence on the management of cardiac arrest patients being treated at the University of Pittsburgh Medical Center (UPMC), where the lead researcher is also a practicing emergency medicine physician.

Cardiac arrest is the sudden, abrupt loss of heart function. Death usually occurs within minutes unless cardiopulmonary resuscitation (CPR) and rapid defibrillation is available. As cardiac arrest progresses, blood flow to the brain ceases. If a patient survives long enough to make it to the hospital, the patient often will be in a coma and at risk of permanent brain injury. In fact, less than 10 percent of patients make it through the chain-of-survival (early access to care, early CPR, early defibrillation and early advanced care). The Pitt researchers sought to find out if hypothermia treatment played a role in survival from cardiac arrest and brain recovery.

In animal studies, the researchers found that when the animals were cooled to 33 degrees Celsius (91.4 degrees Fahrenheit) beginning one hour after cardiac arrest, there was 100 percent survival, whereas 75 percent of the animals left at normal temperature of 37C (98.6F) survived. Furthermore, microscopic brain injury was reduced by half, and some animals showed functional improvement in as little as 12 hours after cardiac arrest was induced. Conversely, the animals left at normal temperature after cardiac arrest showed little or no functional improveme
'"/>

Contact: Maureen McGaffin
412-647-3555
University of Pittsburgh Medical Center
30-May-2003


Page: 1 2

Related biology news :

1. Atacama rover helps NASA learn to search for life on Mars
2. Reducing allergens in the home helps inner-city children with asthma
3. As informatics grows, Indiana University helps set research agenda
4. New diagnostic technology helps justify earlier cataract surgery
5. New technique helps scientists reveal interactions between genes and drugs
6. Living at home helps young mothers stay in school
7. Hormone helps fish to mate, may affect human hearing
8. Harmless virus helps slow HIV by boosting immune proteins
9. Study helps explain island populations susceptibility to exotic diseases
10. Utah scientist helps discover new mouse species -- and maybe a new genus
11. Choice of food helps hungry caterpillar

Post Your Comments:
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: